Get startedLog in
    Picture of Abbisko Cayman logo

    2256 — Abbisko Cayman News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    All News

    Brief: Abbisko Cayman Says Unit's FGFR Inhibitor ABSK121 Got U.S. FDA's Clinical Trial Approval

    Picture of Abbisko Cayman logoAbbisko Cayman
    01/11/2022 01:05
    Nov 1 (Reuters) - Abbisko Cayman Ltd  2256.HK :
    * FGFR INHIBITOR ABSK121 OF ABBISKO THERAPEUTICS GRANTED
CLINICAL
TRIAL APPROVAL BY U.S. FDA

Further company coverage:  2256.HK 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Abbisko Cayman

    See all news